Federal Register / Vol. 76, No. 160 / Thursday, August 18, 2011 / Notices 51399 

No comments, objections, or requests 

for any hearings will be accepted on any 

application for registration or reregistration to import crude opium, 

poppy straw, concentrate of poppy 

straw, and coca leaves. As explained in 

the Correction to Notice of Application 

pertaining to Rhodes Technologies, 72 

FR 3417 (2007), comments and requests 

for hearings on applications to import 

narcotic raw material are not 

appropriate. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances listed in schedule I or II, 

which fall under the authority of section 

1002(a)(2)(B) of the Act 21 U.S.C. 

952(a)(2)(B) may, in the circumstances 

set forth in 21 U.S.C. 958(i), file 

comments or objections to the issuance 

of the proposed registration and may, at 

the same time, file a written request for 

a hearing on such application pursuant 

to 21 CFR 1301.43 and in such form as 

prescribed by 21 CFR 1316.47. 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than September 19, 2011. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

40 FR 43745, all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: August 11, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–21117 Filed 8–17–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on May 4, 

2011, Cambrex Charles City, 1205 11th 

Street, Charles City, Iowa 50616–3466, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as an importer of 

Noroxymorphone (9668), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to import the 

basic class of controlled substance in 

bulk for sale to its customers. 

Any bulk manufacturers who are 

presently, or are applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than September 19, 2011. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

40 FR 43745, all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: August 10, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–21121 Filed 8–17–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to Title 21, of the CFR 

1301.34(a), this is notice that on June 8, 

2011, Aptuit, 10245 Hickman Mills 

Drive, Kansas City, Missouri 64137, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) for registration as an importer of 

the following basic classes of controlled 

substances: 

Drug Schedule 

Marihuana (7360) ......................... I 

Poppy Straw Concentrate (9670) II 

The company plans to import a 

finished pharmaceutical product 

containing cannabis extracts in dosage 

form for packaging for a clinical trial 

study. In addition, the company also 

plans to import an ointment for the 

treatment of wounds which contain 

trace amounts of the controlled 

substances normally found in poppy 

straw concentrate for packaging and 

labeling for clinical trials. 

No comments, objections, or requests 

for any hearings will be accepted on any 

application for registration or reregistration to import crude opium, 

poppy straw, concentrate of poppy 

straw or coca leaves. As explained in 

the Correction to Notice of Application 

pertaining to Rhodes Technologies, 72 

FR 3417(2007), comments and requests 

for hearings on applications to import 

narcotic raw material are not 

appropriate. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances listed in schedule I or II, 

which fall under the authority of section 

1002(a)(2)(B) of the Act (21 U.S.C. 

952(a)(2)(B)) may, in the circumstances 

set forth in 21 U.S.C. 958(i), file 

comments or objections to the issuance 

of the proposed registration, and may, at 

the same time, file a written request for 

a hearing on such application pursuant 

to 21 CFR 1301.43 and in such form as 

prescribed by 21 CFR 1316.47. 

mstockstill on DSK4VPTVN1PROD with NOTICES

51400 Federal Register / Vol. 76, No. 160 / Thursday, August 18, 2011 / Notices 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than September 19, 2011. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

40 FR 43745, all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: August 9, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–21068 Filed 8–17–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated May 13, 2011, and 

published in the Federal Register on 

May 27, 2011, 76 FR 30968, Almac 

Clinical Services Inc., (ACSI), 25 Fretz 

Road, Souderton, Pennsylvania 18964, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as an importer of 

the following basic classes of controlled 

substances: 

Drug Schedule 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Tapentadol (9780) ........................ II 

Fentanyl (9801) ............................ II 

The company plans to import small 

quantities of the listed controlled 

substances in dosage form to conduct 

clinical trials. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a), 

and determined that the registration of 

Almac Clinical Services Inc. (ACSI) to 

import the basic classes of controlled 

substances is consistent with the public 

interest, and with United States 

obligations under international treaties, 

conventions, or protocols in effect on 

May 1, 1971. DEA has investigated 

Almac Clinical Services Inc. (ACSI) to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: August 11, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–21077 Filed 8–17–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By a Notice dated April 28, 2011, and 

published in the Federal Register on 

May 4, 2011 76 FR 25374, Rhodes 

Technologies, 498 Washington Street, 

Coventry, Rhode Island 02816, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of the 

following basic classes of controlled 

substances: 

Drug Schedule 

Raw Opium (9600) .............................................................................................................................. II 

Concentrate of Poppy Straw (9670) .................................................................................................... II 

The company plans to import the 

listed controlled substances in order to 

bulk manufacture controlled substances 

in Active Pharmaceutical Ingredient 

(API) form. The company distributes the 

manufactured API’s in bulk form only to 

its customers. 

As explained in the Correction to 

Notice of Application pertaining to 

Rhodes Technologies, 72 FR 3417 

(2007), comments and requests for 

hearings on applications to import 

narcotic raw material are not 

appropriate. 

DEA has considered the factors in 21 

U.S.C. 823(a) and 952(a), and 

determined that the registration of 

Rhodes Technologies to import the basic 

classes of controlled substances is 

consistent with the public interest, and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971. DEA 

has investigated Rhodes Technologies to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: August 11, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–21076 Filed 8–17–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a), Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on June 17, 2011, 

Cambridge Isotope Lab, 50 Frontage 

Road, Andover, Massachusetts 01810, 

made application by renewal to the 

mstockstill on DSK4VPTVN1PROD with NOTICES